Alnylam Pharma (ALNY) Tops Q3 EPS by $2.38
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of $2.90, $2.38 better than the analyst estimate of $0.52. Revenue for the quarter came in at $1.25 billion versus the consensus estimate of $946.73 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- Phillips 66, Marathon Merger Talks Collapsed - Semafor
- AI/ML Innovations plans $2M private placement on the CSE
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
